Wegovy Butt: Why It Happens and How to Fix It

“Wegovy butt” is the social-media name for a deflated, flattened, or sagging backside after fast weight loss on Wegovy (semaglutide 2.4 mg — the obesity dose of the same molecule sold for type 2 diabetes as Ozempic). It is not a toxic effect of semaglutide on the buttocks. It is the cosmetic consequence of three things happening at once: the subcutaneous fat that gave the buttocks their roundness shrinks, a meaningful share of the weight lost is lean (muscle) mass — roughly a quarter of total weight loss across GLP-1 body-composition data (Look 2025^[1]) — so the gluteal muscles get smaller, and the previously stretched skin over a now-smaller area drapes and looks loose. Wegovy drives a large average weight loss — about −14.9% body weight at the 2.4 mg dose in the STEP-1 pivotal trial (Wilding 2021^[2]) — though typically somewhat less than tirzepatide, so “Wegovy butt” is real but usually less extreme than “Zepbound” or “Mounjaro butt.” It belongs to the same family as “Ozempic face.” The good news: the part you most control — the muscle — responds to the two interventions with the strongest evidence: resistance training and adequate protein.

What "Wegovy butt" actually is

“Wegovy butt” is a colloquial, not a medical, term. It describes a buttocks that looks smaller, flatter, softer, or saggier after substantial weight loss on semaglutide (Wegovy, or its lower-dose diabetes twin Ozempic). People notice it as loss of projection and fullness, a “deflated” quality, crepey or loose skin over the upper thigh and lower glute, and sometimes a more pronounced fold where the buttock meets the thigh.

The crucial point is that this is not a drug toxicity aimed at the gluteal region. Semaglutide has no known pharmacological action on buttock tissue specifically. It is the same phenomenon described for decades after bariatric surgery, very-low-calorie diets, and any other route to fast, large weight loss. Wegovy draws attention because it produces large, rapid weight loss — an average of about −14.9% body weight at 2.4 mg over 68 weeks in the STEP-1 pivotal trial (Wilding 2021^[2]) — so the body-composition change is simply more visible, faster. That figure is large but, on average, somewhat smaller than tirzepatide's roughly −20.9% at 15 mg in SURMOUNT-1 (Jastreboff 2022^[3]), which is why “Wegovy butt” tends to look less dramatic than “Mounjaro butt” — same mechanism, smaller average scale.

Why it happens — fat loss, lean-mass loss, and skin laxity

1. Subcutaneous gluteal fat shrinks

The roundness and projection of the buttocks come largely from the gluteofemoral subcutaneous fat depot. This depot is metabolically distinct from belly fat — it is generally protective and slower to mobilize (Manolopoulos 2010^[4]) — but during a sustained, large caloric deficit it does shrink along with the rest of the body's fat stores. Because the buttock is a high-fat, low-other-tissue area, losing that subcutaneous fat has an outsized visual effect: there is less underneath to fill out the skin. On Wegovy, this is the single biggest driver of the deflated look — and to a large degree it is the intended result of the weight loss, the same fat loss that improves metabolic health.

2. A share of the weight lost is muscle

Every weight-loss method — diet, surgery, or GLP-1 — takes some lean (muscle) tissue along with the fat. The best DXA body-composition data in the class come from the SURMOUNT-1 substudy (Look 2025^[1]), where about 25% of the total weight lost was lean tissue — and the placebo arm showed the same fat-to-lean split, confirming the ratio reflects rate-of-weight-loss physiology, not a drug-specific effect. Semaglutide in STEP-1 showed the same pattern: fat mass fell more than lean mass, but lean mass still made up a meaningful share of the loss (Wilding 2021^[2]). When the gluteus maximus and surrounding muscles lose volume, the buttocks lose their underlying shape and lift. Our GLP-1 muscle-loss prevention protocol covers the body-composition evidence in full.

3. Skin that was stretched now drapes

Skin that has been stretched over a larger volume for a long time does not always retract fully when the volume underneath disappears, especially with faster loss, larger total loss, older age, sun damage, and genetics. The result is laxity — crepey, loose, or sagging skin over the lower buttock and upper thigh. See our guide on how to tighten loose skin after weight loss.

Put the three together — less fat, less muscle, looser skin — and you get the characteristic flattened, softened backside. The fat loss is mostly desired; the muscle loss and skin laxity are the parts worth actively managing.

The body-composition evidence: how much of Wegovy weight loss is lean mass

The honest, sourced numbers matter here, because the “muscle” part of “Wegovy butt” is the part you can most influence.

• Semaglutide (STEP-1, Wilding 2021^[2]): −14.9% total body weight at week 68, with a DXA pattern in the typical range — fat mass dropped more than lean mass, but lean mass still accounted for a meaningful share of the loss. This is the Wegovy dose (2.4 mg once weekly).
• The 25% lean fraction (SURMOUNT-1 DXA substudy, Look 2025^[1]): the most detailed DXA dataset in the class found roughly 25% of total weight lost was lean tissue, with the same 75/25 fat-to-lean split in the placebo arm — a ratio that applies across GLP-1 weight loss, including semaglutide.
• Magnitude is where Wegovy differs from Mounjaro: semaglutide 2.4 mg averages about −14.9% (Wilding 2021^[2]) versus tirzepatide's roughly −20.9% at 15 mg (Jastreboff 2022^[3]). A similar lean fraction of a smaller total loss means less absolute muscle is at stake — so “Wegovy butt” is real but typically less extreme.
• Across all modalities (Cava 2017^[5]): the lean-tissue fraction of weight lost clusters around 20–30% for moderate-rate loss and tilts higher with faster loss — semaglutide weight loss is not an outlier in its ratio.
• Rate matters: faster weight loss tends to take a higher proportion of lean tissue, which is why slower titration and protein-plus-training are the levers (Stefanakis 2024^[9]).

The takeaway for the buttocks specifically: roughly a quarter of what you lose is, by default, lean mass — and the gluteal muscles are a large, visible muscle group. Protect that muscle and you protect a large part of the shape.

How to AVOID it — protect muscle while you lose fat

You cannot lose 10–15% of your body weight without some change to the buttocks — the fat that gave it volume is part of what is coming off. But you can substantially change how much of the loss is muscle versus fat, and you can preserve the underlying shape. Three interventions have the strongest evidence.

1. Resistance training, with glute-focused work, 2–3 sessions per week. This is the single highest-evidence intervention. Sardeli 2018^[6] meta-analyzed RCTs of resistance training during caloric restriction and found it essentially abolished the lean-mass loss otherwise seen with diet alone. Murphy and Koehler 2022^[10] showed that even in an energy deficit, resistance training still attenuates lean-mass loss and preserves strength. For the buttocks, prioritize compound lower-body movements that load the glutes — squats, hip hinges (deadlift, Romanian deadlift), and hip thrusts — alongside a full-body program.
2. Protein at 1.2–1.6 g/kg per day (up to ~2.0 g/kg on a GLP-1). Krieger 2006^[7] and Phillips 2016^[8] converge on roughly 1.6 g/kg as the practical target for preserving fat-free mass in a deficit; Longland 2016^[11] randomized men in a steep deficit to higher versus lower protein and the high-protein arm actually gained lean mass while losing fat; Wycherley 2012^[12] confirmed higher-protein diets reduce fat-free-mass loss. The challenge on Wegovy is hitting the target when appetite is strongly suppressed — semaglutide's appetite effect is potent, so prioritize protein first at each meal.
3. Slower titration / slower rate of loss, where appropriate. Because faster loss takes proportionally more lean tissue, and Wegovy is titrated upward over months to the 2.4 mg dose, discussing a more gradual dose escalation with your prescriber can reduce the share of weight lost as muscle and give skin more time to adapt (Stefanakis 2024^[9]).

How to FIX it — rebuild, tighten, and the cosmetic options

Rebuild the muscle (the highest-leverage fix)

The most effective and lowest-risk way to restore shape is to rebuild the gluteal muscle with progressive resistance training. Unlike fat loss, muscle can be regained, and the glutes respond strongly to direct loading. A program built around hip thrusts, squats, hip hinges, and lunges — 2–3 sessions per week with progressive overload — rebuilds the underlying volume and lift over weeks to months. Pairing this with adequate protein is what turns training into actual muscle. This is the same protocol used to prevent the change, applied after the fact; it works best once weight has stabilized so you are no longer in a steep deficit — relevant on Wegovy, where the titration and weight-loss phase runs many months.

Skin tightening

Skin laxity is harder to reverse than muscle loss. Mild laxity often improves over months as skin slowly retracts, helped by reaching a stable weight, staying hydrated, not smoking, and protecting skin from sun. For more significant laxity, non-surgical energy-based devices (radiofrequency and ultrasound-based skin-tightening) are used cosmetically, and surgical options for the body exist for substantial excess skin — the post-bariatric body-contouring literature (Sadeghi 2022^[13]) describes these procedures, though most published work focuses on the abdomen and arms rather than the buttocks specifically. See our dedicated guide on tightening loose skin after weight loss.

Cosmetic volume restoration (elective)

If muscle rebuilding and skin tightening do not fully restore the desired shape, several elective cosmetic procedures can add volume. These are aesthetic, optional, and carry their own costs and risks — described here neutrally, not recommended:

• Autologous fat transfer (Brazilian butt lift, BBL): liposuctioned fat from elsewhere is injected into the buttocks to restore volume and projection. With rapid weight loss, results depend on having enough donor fat left and on weight stability afterward.
• Biostimulatory injectables: agents such as poly-L-lactic acid and calcium hydroxylapatite are used off the face to stimulate collagen and add gradual volume to areas including the buttocks. These are non-surgical but require a series of sessions and have temporary results.
• Surgical gluteal augmentation / lift: for combined volume loss and significant skin excess, plastic surgeons offer buttock lift and augmentation procedures, sometimes alongside body-contouring after major weight loss.

For any of these, the practical advice mirrors the “Ozempic face” guidance: time cosmetic intervention after weight has stabilized for a few months, because treating before the target weight is reached produces volume mismatches that need re-treatment as more weight comes off. Bring your starting weight, current weight, and titration plan to the consultation.

Why muscle preservation matters beyond appearance

The gluteal and leg muscles are not only cosmetic — they are central to strength, balance, and metabolic health. Excess lean-mass loss matters most in older adults and in anyone at risk of sarcopenia (age-related muscle loss). The EWGSOP2 (Cruz-Jentoft 2019^[14]) and ESPEN/EASO sarcopenic-obesity (Donini 2022^[15]) consensus statements define when to screen muscle strength and mass formally — relevant for patients age 65 or older or with low baseline strength starting Wegovy. The same resistance training and protein that keep the buttocks shapely also protect function and reduce fall and frailty risk. That is the strongest reason to treat the muscle side of “Wegovy butt” seriously rather than purely cosmetically.

How does "Wegovy butt" compare to "Mounjaro butt"?

Both are the same underlying phenomenon — rapid weight loss made visible in a high-fat, low-other-tissue area — and the prevention and treatment logic is identical. The difference is scale. Tirzepatide (Mounjaro, Zepbound) produces the largest average weight loss of the GLP-1 class, about −20.9% at 15 mg in SURMOUNT-1 (Jastreboff 2022^[3]), versus semaglutide's roughly −14.9% at the Wegovy 2.4 mg dose in STEP-1 (Wilding 2021^[2]). Because a similar lean fraction (around 25%) is removed from a smaller total loss on Wegovy, less absolute fat and muscle come off the buttocks on average, so “Wegovy butt” is typically less extreme than “Mounjaro butt” — though individual results vary widely. See the Mounjaro butt and Ozempic butt articles for the side-by-side mechanism.

Bottom line

• “Wegovy butt” is the deflated, flattened, or sagging buttocks seen after rapid semaglutide weight loss — a body-composition and skin effect, not a drug toxicity to the buttocks, and not an injection-site issue (Wegovy is injected in the abdomen, thigh, or upper arm).
• It is driven by three things: loss of gluteal subcutaneous fat, loss of gluteal muscle (about 25% of GLP-1 weight loss is lean mass per the SURMOUNT-1 DXA substudy^[1]), and skin laxity over a previously stretched area.
• It is real but typically less extreme than “Mounjaro butt,” because semaglutide's average loss (−14.9% in STEP-1, Wilding 2021^[2]) is somewhat smaller than tirzepatide's (−20.9% at 15 mg, Jastreboff 2022^[3]), so a similar lean fraction removes less absolute muscle.
• To avoid it: resistance training with glute-focused work 2–3x/week (Sardeli 2018^[6]), protein 1.2–1.6 g/kg (up to ~2.0 on a GLP-1), and slower titration where appropriate.
• To fix it: rebuild glute muscle with progressive resistance training (the highest-leverage, lowest-risk fix), support skin retraction, and — if desired — consider elective cosmetic options (fat transfer/BBL, biostimulators, surgical lift) once weight is stable.
• Preserving muscle protects strength, balance, and metabolic health, especially in older adults at risk of sarcopenia (Cruz-Jentoft 2019^[14]).

Related research

• Ozempic butt — the same mechanism on semaglutide's diabetes-brand twin.
• Mounjaro butt — the higher-magnitude version on tirzepatide, for comparison.
• Preventing muscle loss on a GLP-1 — the resistance-training and protein protocol that protects the glutes.
• Tightening loose skin after weight loss — options for the skin-laxity component.
• Ozempic face — the same subcutaneous-fat-loss mechanism in the face, imaging-quantified.

Important disclaimer. This article is educational and does not constitute medical, exercise, or cosmetic-procedure advice. Wegovy (semaglutide 2.4 mg) is approved for chronic weight management; the same molecule is approved for type 2 diabetes as Ozempic. Resistance-training programs should be individualized and, for patients with cardiovascular disease, prior injury, or significant deconditioning, supervised by a qualified clinician or certified strength coach. Protein targets assume normal renal function. Cosmetic and surgical procedures are elective and carry their own risks; discuss them with a board-certified provider. Every primary source cited here was verified against the live PubMed E-utilities API on 2026-06-20.